These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28560349)

  • 1. Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53.
    Miyamoto T; Lo PHY; Saichi N; Ueda K; Hirata M; Tanikawa C; Matsuda K
    Sci Adv; 2017 May; 3(5):e1603204. PubMed ID: 28560349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
    Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
    Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Argininosuccinate synthetase 1 contributes to gastric cancer invasion and progression by modulating autophagy.
    Tsai CY; Chi HC; Chi LM; Yang HY; Tsai MM; Lee KF; Huang HW; Chou LF; Cheng AJ; Yang CW; Wang CS; Lin KH
    FASEB J; 2018 May; 32(5):2601-2614. PubMed ID: 29401583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.
    Long Y; Tsai WB; Chang JT; Estecio M; Wangpaichitr M; Savaraj N; Feun LG; Chen HH; Kuo MT
    Oncotarget; 2016 Dec; 7(50):82658-82670. PubMed ID: 27765932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASS1 metabolically contributes to the nuclear and cytosolic p53-mediated DNA damage response.
    Lim LQJ; Adler L; Hajaj E; Soria LR; Perry RB; Darzi N; Brody R; Furth N; Lichtenstein M; Bab-Dinitz E; Porat Z; Melman T; Brandis A; Malitsky S; Itkin M; Aylon Y; Ben-Dor S; Orr I; Pri-Or A; Seger R; Shaul Y; Ruppin E; Oren M; Perez M; Meier J; Brunetti-Pierri N; Shema E; Ulitsky I; Erez A
    Nat Metab; 2024 Jul; 6(7):1294-1309. PubMed ID: 38858597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Argininosuccinate synthase 1 suppresses tumor progression through activation of PERK/eIF2α/ATF4/CHOP axis in hepatocellular carcinoma.
    Kim S; Lee M; Song Y; Lee SY; Choi I; Park IS; Kim J; Kim JS; Kim KM; Seo HR
    J Exp Clin Cancer Res; 2021 Apr; 40(1):127. PubMed ID: 33838671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
    Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
    Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic adenosine monophosphate-induced argininosuccinate synthase 1 expression is essential during mouse decidualization.
    Huang Z; Wang TS; Zhao YC; Zuo RJ; Deng WB; Chi YJ; Yang ZM
    Mol Cell Endocrinol; 2014 May; 388(1-2):20-31. PubMed ID: 24556046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
    Allen MD; Luong P; Hudson C; Leyton J; Delage B; Ghazaly E; Cutts R; Yuan M; Syed N; Lo Nigro C; Lattanzio L; Chmielewska-Kassassir M; Tomlinson I; Roylance R; Whitaker HC; Warren AY; Neal D; Frezza C; Beltran L; Jones LJ; Chelala C; Wu BW; Bomalaski JS; Jackson RC; Lu YJ; Crook T; Lemoine NR; Mather S; Foster J; Sosabowski J; Avril N; Li CF; Szlosarek PW
    Cancer Res; 2014 Feb; 74(3):896-907. PubMed ID: 24285724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depression of p53-independent Akt survival signals in human oral cancer cells bearing mutated p53 gene after exposure to high-LET radiation.
    Nakagawa Y; Takahashi A; Kajihara A; Yamakawa N; Imai Y; Ota I; Okamoto N; Mori E; Noda T; Furusawa Y; Kirita T; Ohnishi T
    Biochem Biophys Res Commun; 2012 Jul; 423(4):654-60. PubMed ID: 22695120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Citrulline depletion by ASS1 is required for proinflammatory macrophage activation and immune responses.
    Mao Y; Shi D; Li G; Jiang P
    Mol Cell; 2022 Feb; 82(3):527-541.e7. PubMed ID: 35016033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival.
    Fenouille N; Puissant A; Tichet M; Zimniak G; Abbe P; Mallavialle A; Rocchi S; Ortonne JP; Deckert M; Ballotti R; Tartare-Deckert S
    Oncogene; 2011 Dec; 30(49):4887-900. PubMed ID: 21685937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
    Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
    Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial argininosuccinate synthetase is dispensable for intestinal regeneration and tumorigenesis.
    van der Meer JHM; de Boer RJ; Meijer BJ; Smit WL; Vermeulen JLM; Meisner S; van Roest M; Koelink PJ; Dekker E; Hakvoort TBM; Koster J; Hawinkels LJAC; Heijmans J; Struijs EA; Boermeester MA; van den Brink GR; Muncan V
    Cell Death Dis; 2021 Oct; 12(10):897. PubMed ID: 34599156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naturally-occurring spinosyn A and its derivatives function as argininosuccinate synthase activator and tumor inhibitor.
    Zou Z; Hu X; Luo T; Ming Z; Chen X; Xia L; Luo W; Li J; Xu N; Chen L; Cao D; Wen M; Kong F; Peng K; Xie Y; Li X; Ma D; Yang C; Chen C; Yi W; Liu O; Liu S; Luo J; Luo Z
    Nat Commun; 2021 Apr; 12(1):2263. PubMed ID: 33859183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-application of canavanine and irradiation uncouples anticancer potential of arginine deprivation from citrulline availability.
    Kurlishchuk Y; Vynnytska-Myronovska B; Grosse-Gehling P; Bobak Y; Manig F; Chen O; Merker SR; Henle T; Löck S; Stange DE; Stasyk O; Kunz-Schughart LA
    Oncotarget; 2016 Nov; 7(45):73292-73308. PubMed ID: 27689335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1.
    Locke M; Ghazaly E; Freitas MO; Mitsinga M; Lattanzio L; Lo Nigro C; Nagano A; Wang J; Chelala C; Szlosarek P; Martin SA
    Cell Rep; 2016 Aug; 16(6):1604-1613. PubMed ID: 27452468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASS1 inhibits triple-negative breast cancer by regulating PHGDH stability and de novo serine synthesis.
    Luo W; Zou Z; Nie Y; Luo J; Ming Z; Hu X; Luo T; Ouyang M; Liu M; Tang H; Xie Y; Peng K; Chen L; Zhou J; Luo Z
    Cell Death Dis; 2024 May; 15(5):319. PubMed ID: 38710705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance.
    Kim Y; Kobayashi E; Kubota D; Suehara Y; Mukaihara K; Akaike K; Ito A; Kaneko K; Chuman H; Kawai A; Kitano S
    Oncotarget; 2016 Oct; 7(43):70832-70844. PubMed ID: 27683125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
    Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
    Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.